NOVARTIS recalled H1N1 vaccine two months before alleged H1N1 outbre
Posted by: "Ingrid Blank" enb1@telkomsa.net zauberfeechen
Mon Jul 20, 2009 5:06 am (PDT)


They started producing cell-based OPTAFLU vaccine (cultured on the kidney
cells of a dead Spaniel) in Germany in 2007 and according to the product
information sheet that concoction give false-positive HIV readings!

Ingrid

http://birdflu666.wordpress.com/

July 19, 2009 by birdflu666
Novartis recalled its “swine flu” HIN1 vaccine in February of this year, two
months before the outbreak of the allegedly new and unseeen “swine flu” H1N1
outbreak in Mexico City occurred in April.

The timing of the recall of the H1N1 vaccine raises questions concerning how
Novartis could have had a vaccine for the “swine flu” H1N1 virus on the
market months before this allegedly new and dangerous “swine flu” virus
appeared in Mexico in April. The appearance of the H1N1 virus was allegedly
so new and so dangerous that WHO felt obliged to declare a pandemic
emergency level 6 even though there’ve been hardly any deaths around the
globe officially attributed to the so-called “swine flu”.

As a result of this declaration of a pandemic level 6 emergency, WHO’s
vaccine advisory group packed with executives from Baxter and Novartis
recommended worldwide vaccination, a recommendation WHO translated into a
guideline with legal force.

Now, billions of people around the world face the prospect of a mandatory
vaccination with unproven, toxic substances for a harmless virus that has
been bioengineered to be lethal.

Novartis is also planning to have MF 59 or squalene in its vaccine, a toxic
adjuvant.

Novartis “bird flu” vaccine, which killed at least 20 people in Poland last
summer, has “adverse events reactions” listed as its “primary outcome
measure” on the database of clinical trials.

Novartis’ CEO Daniel Vassella was at the Bilderberg meeting in Athens this
May together with Austrian Chancellor Werner Faymann. Were they discussing
plans to coordinate the activities of the Austrian government, Baxter’s
Austrian subsidiary and other vaccine companies such as Novartis to
implement forced vaccination in the autumn in response to the media frenzy
whipped up by the appearance of a virus in Mexico that Novartis had a
vaccine for anyway months before?

It was Baxter’s Austrian subsidiary that contaminated 72 pounds of vaccine
material with live bird flu virus this February and sent it out to 16 labs
in four countries, thereby nearly triggering a pandemic.

—-

MANUFACTURER:

Novartis Vaccines and Diagnostics Limited
Liverpool United Kingdom

REASON:

Novartis Vaccines and Diagnostics Inc. has requested their customers to
immediately discontinue use of and return any remaining doses they may have
from five lots of FLUVIRIN® Influenza vaccine Luer-Lok pre-filled syringes.

Routine stability testing of FLUVIRIN in prefilled Luer-Lok syringes
revealed a minor deviation in the potency of the A/Brisbane (H1N1) component
of the vaccine. The vaccine met all required specifications at the time of
release and has been monitored in monthly time intervals during its shelf
life; it has consistently met specification until the most recent test point
in early January 2009 that identified a minimal decrease in H1N1 antigen
content.

The Food and Drug Administration (FDA), the Centers for Disease Control and
Prevention (CDC), and Novartis Vaccines have agreed that no public health
impact is expected because 1) all of the affected vaccine was shipped when
the vaccine met potency requirements, 2) most influenza vaccine in the US is
administered during October and November, months when the vaccine met
potency requirements, and 3) the decrease in antigen content is small and
would have a negligible if any effect on immune response to vaccination.
Revaccination of patients that have been vaccinated with the affected lots
is not necessary.